Discussion
Jasper Therapeutics has announced its acquisition of Kira Pharmaceuticals in a deal that will provide new resources and expertise to help advance the late-stage clinical development of KP104, a treatment candidate for paroxysmal nocturnal hemoglobinuria (PNH), as well as other experimental therapies involving the immune system. For…